Intracorporeal urinary diversion (ICUD) is associated with similar postoperative complication rates, reduced blood loss and shorter hospitalization vs extracorporeal urinary diversion (ECUD) in patients undergoing robotic-assisted radical cystectomy (RARC) for localized bladder cancer, data from the Asian RARC Consortium registry have shown.
Vaccination against SARS-CoV-2 appears to lead to favourable outcomes in multiple myeloma (MM) patients who contract the coronavirus disease 2019 (COVID-19), even in the presence of negative prognostic factors, a recent study has found.
Adipose tissue radiodensity is significantly associated with the risk of death in patients with nonmetastatic colorectal cancer (CRC), independent of body mass index and changes in body weight, results of a study have shown.
In women with hormone-receptor positive advanced breast cancer (HR+ aBC), the addition of the class I selective histone deacetylase (HDAC) inhibitor entinostat to exemestane appeared to be better than treatment with exemestane alone in terms of survival benefit, according to a phase III trial from China.
Non-Hodgkin lymphoma (NHL), particularly follicular and mature T/NK-cell lymphomas, is more likely to develop among patients with breast cancer, a recent study has found. Moreover, such risk is greater among those who had been treated with hormone therapy.
Dietary intake of the common food additive nitrates and nitrites, trans fatty acids, and artificial sweeteners was associated with an increased risk of multiple cancers, according to data from the large NutriNet-Santé cohort presented at SABCS 2021.
The novel oral SERD* elacestrant demonstrated potential as new treatment alternative for ER+/HER2– advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy, according to the phase III EMERALD trial.
Though decreasing over time, early mortality remains high in patients with multiple myeloma (MM), a recent study has found. Important risk factors include older age, a more aggressive disease, and a patient’s poor physical condition.
Treating myeloproliferative neoplasm patients with direct oral anticoagulants (DOACs) may induce higher risks of bleeding events, with no particular spikes in thrombosis rates, a recent study has found.